Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Conditions: Lung Cancer, Nonsmall Cell; Esophageal Carcinoma Interventions: Drug: Camrelizumab; Drug: Thalidomide 50mg; Drug: Thalidomide 100mg; Drug: Thalidomide 200mg; Drug: Chemotherapy Sponsors: Henan Cancer Hospital; First Affiliated Hospital Xi ' an Jiaotong University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials